Common Contracts

UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases

Global License Agreement • November 29th, 2021

• Contract Type
  Global License Agreement
• Filed
  November 29th, 2021

• UCB has granted to Chiesi global exclusive rights to develop, manufacture and commercialize zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases